Clinical Trials
22 trialsNCT06561048 2026-04-08
Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma
Corvus Pharmaceuticals, Inc.
Phase 3 Recruiting
NCT06522737 2026-04-06
TERZO
SecuraBio
Phase 3 Recruiting
NCT07300514 2026-03-31
T-START-M1
Fudan University
Phase 3 Recruiting
NCT07414758 2026-02-24
T-START-M1
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Phase 3 Recruiting
NCT06776952 2026-01-09
A Randomized, Double-blind, Multicenter Phase III Study of XNW5004 Tablets in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma
Evopoint Biosciences Inc.
Phase 3 Recruiting
NCT07258680 2025-12-02
BrEto-TCL
N.N. Petrov National Medical Research Center of Oncology
Phase 3 Enrolling by invitation
NCT07234162 2025-11-18
A Phase 3 Multinational Study of Golidocitinib Versus Investigator's Choice in r/r PTCL (JACKPOT19)
Dizal Pharmaceuticals
Phase 3 Recruiting
NCT06072131 2025-10-23
CRESCENDO
Acrotech Biopharma Inc.
Phase 3 Recruiting
NCT06947967 2025-09-15
Tucidinostat in Combination With CHOP in Newly Diagnosed Peripheral T-Cell Lymphoma With Follicular Helper of T Cell Phenotype
Chipscreen Biosciences, Ltd.
Phase 3 Recruiting
NCT04668690 2025-05-31
Clinical Study of Mitoxantrone Hydrochloride Liposome Injection vs. Chidamide in Patients With Relapsed/Refractory PTCL
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase 3 Active not recruiting
NCT01796002 2023-01-10
Efficacy and Safety of Romidepsin CHOP vs CHOP in Patients With Untreated Peripheral T-Cell Lymphoma
The Lymphoma Academic Research Organisation
Phase 3 Completed
NCT01420679 2021-11-19
Pralatrexate vs Observation Following CHOP-based Chemotherapy in Undiagnosed Peripheral T-cell Lymphoma Patients
Spectrum Pharmaceuticals, Inc
Phase 3 Terminated
NCT04880746 2021-05-11
Efficacy and Safety of Cladribine Combined With BEAC Pretreatment Regimen in the Treatment of Peripheral T-cell Lymphoma: a Multicenter Clinical Study
Ruijin Hospital
Phase 3 Unknown
NCT03349333 2019-10-01
A Single Arm Study Evaluating the Efficacy and Safety of Pralatrexate in Subjects With Relapsed or Refractory PTCL
Mundipharma (China) Pharmaceutical Co. Ltd
Phase 3 Completed
NCT03952572 2019-05-16
Efficacy and Safety of CDOP vs CHOP for Newly Diagnosed Peripheral T-cell Lymphoma
Peking University
Phase 3 Unknown
NCT00646854 2019-03-01
ACT-1
University of Aarhus
Phase 3 Completed
NCT03355768 2018-12-19
Romidepsin Versus Combination of Romidepsin Plus Pralatrexate in PTCL
Columbia University
Phase 3 Withdrawn
NCT01482962 2018-07-31
Alisertib (MLN8237) or Investigator's Choice in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma
Takeda
Phase 3 Completed
NCT03553537 2018-06-12
Efficacy and Safety of Decitabine Plus CHOP vs CHOP in Patients With Untreated Peripheral T-Cell Lymphoma
Southwest Hospital, China
Phase 3 Unknown
NCT03023358 2017-01-18
Compared the Efficacy and Safety of CDOP Combined With Chidamide and CDOP in de Novo Peripheral T Cell Lymphoma Patients
Nanfang Hospital, Southern Medical University
Phase 3 Unknown
NCT01355783 2013-11-18
A Phase 3 Trial of E7777 in Combination With CHOP Compared With CHOP Alone for the First-Line Treatment of Peripheral T-cell Lymphoma
Eisai Inc.
Phase 3 Withdrawn
NCT00970385 2009-09-09
LTP
University Hospital, Grenoble
Phase 3 Completed